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The first investigation ofthe central-type benzodiazepine (BZ) receptor density be~hre and following 2 months 
successful treatment with carbamazepine (CBZ) in a patient with temporal lobe epilepsy (TLE) using l~:~I- 
labelled Iomazenil (a specific lipophile central BZ receptor compound) and single photon emission tomography 
ISPET) is reported. First. a focal slowing of the EEG in the left temporal area was noted and a corresponding 
reduction of the central BZ density of the left temporal lobe was found. After 2 months of treatment the patient 
was symptom-free, and a normal BZ receptor density and no pathological EEG signs were found. The increase 
in central BZ receptor binding sites might be related to the anticonvulsant effects of CBZ mediated by the so- 
called peripheral BZ receptor sites. 
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INTRODUCTION 
Presurgical imaging studies have shown that 
about 50~ of patients with focal seizures have 
no visible structural lesions in magnetic 
reasonance imaging (MRI) or computed tom- 
ography (CT) ~. Beside the invasive seizure 
monitoring with depth electrodes imaging 
methods with radiolabelled central benzodiaze- 
pine receptor ligands for positron emission 
tomography (PET} and single-photon emission 
tomography (SPET) may provide a non- 
invasive technique for the localization of seiz- 
ure focus 2-6. Especially the latter is of interest 
since the SPET technique is less expensive and 
more available than PET. In vitro labelling of 
central- {using 125I-Ro 16-O154 = Iomazenil) 
and peripheral-type (using 3H-PK 11195) BZ 
receptors of epileptogenic tissue of patients 
with temporal lobe epilepsy (TLE) refractory to 
anti-epileptic medication and findings of 
mesial temporal sclerosis indicated a decrease 
of central-type and an increase of peripheral- 
type BZ receptor bindings sites 4. These 
changes seem to reflect the regional loss of 
neurons and a proliferation of glia, because the 
central-type is located on neurons and the 
peripheral-type is located on glia cells 4. The 
decreased density of these central-type 
GABAA-BZ receptors may also reflect a 
reduced inhibitory tone in the epileptic tissue. 
To investigate whether this finding changes in 
the course of the therapy especially in therapy 
responders we measured the central-type BZ 
receptor density in a patient with a medi- 
cation-responding TLE. 
PATIENT AND METHOD 
A 37-year-old, otherwise healthy, female 
reporting a 5-year history of obscure daytime 
attacks and frequent fearful awakenings, was 
sent to our sleep laboratory. The patient re- 
ported about attacks which occurred up to five 
times a day. At the beginning of an attack she 
always felt strange followed by fear and move- 
ment arrest for a few seconds with lowering of 
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Fig. 1 : Polysomnogram of a patient with complex partial seizures during sleep. The seizures are marked with arrows. 
Abbreviations: Sleep stages I-IV, R EM = rapid eye movement sleep, W = wake (according Rechtschaffen and Kales 196811). 
consciousness. The seizures occurred also 
during sleep. The symptomatology initially 
classified as an anxiety disorder was unsucess- 
fully treated with clonazepam (lmg/die) and 
pimozide (2mg/die) and the medication was 
therefore withdrawn several months ago~ We 
performed polysomnographic (PSG) and elec- 
troencephalographic (EEG) recordings and 
MRI scans. The central-type BZ receptor bind- 
ing sites were measured with 123I-Iomazenil (a 
high selective central-type BZ receptor ligand 
(Kd0 0.5riM at 37°C)) and SPET before and 
after 2 months of successful treatment with 
carbamazepine (CBZ). An activity dose of 
185 MBq 123I-Iomazenil was administered in- 
travenously 120 minutes before the SPET 
measurement. For data acquisition a rotating 
gamma camera (Picker International) con- 
nected to a Picker Odyssey computer was used. 
A series of 64 images were collected at 6 ° 
increments for 30 seconds each into a 64 × 64 
pixel matrix. 
into account. The seizures were always fol- 
lowed by sleep stage wake. 
The 123I-Iomazenil SPETs were evaluated 
visually for asymmetries by two experienced 
raters, who were blind for the clinical data. In 
the transverse section of the patient we found a 
decreased tracer density in the left temporal 
lobe (Fig. 2, left side). 
Regarding the diagnostic tools, routine EEG, 
SPET and seizure classification revealed a 
localization-related pilepsy with complex par- 
tial seizures with a probable left frontotem- 
poral origin. 
After 2 weeks of treatment with carbamaze- 
pine 200 mg in the morning and 400 mg in the 
evening (serum level: 18.5 ~mol/1) the patient 
was free of seizures and the 2-month follow-up 
SPET showed a normalized symmetrical tracer 
distribution in both temporal lobes (Fig. 2, 
right side). In addition, the control EEGs 
showed no abnormalities under CBZ treat- 
ment. 
RESULTS 
The neurological examination, the MRI scan 
and the routine clinical laboratory techniques 
provided no pathological signs. In routine EEG 
we noted a focal slowing in the left temporal 
area. 
During the video-monitored PSG, several 
complex partial seizures were recorded which 
clinically started with an epigastrial aura, fol- 
lowed by automatisms mainly of the upper ex- 
tremities and lowering of consciousness. The 
seizures occurred six times out of sleep stage H, 
III and IV (Fig. 1), the EEG was overlapped by 
increased EMG activity and could not be taken 
DISCUSSION 
The 123I-Iomazenil SPET of the untreated 
patient indicated a reduced binding of tracer at 
the left temporal lobe. This result could be due 
to changes in the density or sensitivity of ben- 
zodiazepine receptors or result from an in vivo 
competition of an endogenous ligand with the 
radioligand as demonstrated in vivo with dopa- 
mine receptor ligands. 7 First, the reduction of 
central BZ receptor density found in neurosur- 
gical preparations of epileptic tissue points to a 
reduction of BZ receptor binding sites and not 
to a loss of sensitivity in our case 4. Second, 
there is no reason why an endogenous receptor 
ligand should more effectively compete for 
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radioligand binding in just one of the temporal 
lobes. The only explanation would be a low 
regional blood flow, but this would only affect 
initial supply of the radioligand (which also 
has a high receptor affinity}, but not the final 
distribution 120 min after the injection. There- 
fore the reduction of the radioligand binding in 
the left temporal lobe with a corresponding 
EEG focus indicates a loss (downregulation) of
central BZ receptors. The results are in accord- 
ance with a report of Wedel et al. 6, who found, 
using 123I-Iomazenil and SPET, a regional re- 
duction of BZ receptor binding sites, corres- 
ponding with an EEG focus in 16 of 27 patients 
with focal epilepsy. The decreased central BZ 
receptor binding may reflect a reduced inhibi- 
tory tone in the epileptic tissue mediated by a 
loss of neuronal tissue as stated by Johnson et 
al. 4 or functionally dormant GABA cells 8"9. 
The latter point of view is supported by the 
selective expression of the calcium-binding 
protein parvalbumin {PV) in two different 
populations of GABA neurons in tumor-related 
TLE (TTLE) and cryptogenic TLE (CTLE) 
tissue 8. In TTLE, PV is located in neurons 
resembling GABA-ergic pyramidal basket cells 
and subgranular neurons but not in the mol- 
ecular layer neurons as in CTLE. Interest- 
ingly, Sloviter 9 found in his induced seizure 
model in stimulated rats a similar PV ex- 
pression to that in CTLE with no expression of 
PV in the pyramidal basket cell-like neurons. 
He proposed that these non-PV-expressing 
neurons in the GABA pyramidal basket cells 
may characterize them as dormant cells. 
Therefore the decreased GABA-mediated inhi- 
bition in TLE may be related to changes in the 
functional status and not to a loss of GABA 
neurons. Our data, which show a normalized 
symmetrical distribution of the central-type 
BZ receptor density after the successful treat- 
ment with CBZ, support the hypothesis of 
changes in the functional status of GABA-ergic 
neurons. Nevertheless, there may be a differ- 
ence between therapy responders and non-re- 
sponders, especially when mesial sclerosis is 
present 4. The occurrence of a symmetrical BZ 
receptor distribution under successful anticon- 
vulsant treatment with CBZ could possibly be 
mediated by a glial neuronal interaction, 
because its known that in part the anticonvul- 
sant effects of CBZ are mediated through the 
so-called peripheral BZ receptor sites which 
are located on glial cells '°. Whether the re- 
duction of central BZ receptors is constant 
during therapy in non-responders emains to 
be clarified. In our opinion, our data underline 
that 123I-Iomazenil-SPET is an appropriate 
method for such measurements. 
REFERENCES 
1. Lencz, T., McCarthy, G., Bronen, R.A. et al. Quantita- 
tive magnetic resonance imagin~ in temporal lobe epi- 
lepsy: Relationship to neuropathology and neuro- 
psychological function. Annals of Ncu,'ology 1992; 31: 
629-637. 
2. Bartenstein, P., Ludolph. A., Schober, O., Lottes, G., 
B6ttger, I. and Beer. H.-F. Vergletch von BlutfluB und 
Benzodiazepin-Rezeptorverteilung bei fokaler Epilep- 
sic: Vorl~iufige Ergebnisse einer SPECT-Studie. 
Nuclear Medicine 1989; 28: 81-86. 
3. Innis, R.B., AI-Tikriti, M.S., Zoghbi, S.S. et al. SPECT 
imaging of the benzodiazepine receptor: feasibility of 
in vivo potency measurements from stepwise displace- 
ment curves. Journal of Nuclear Medicine 1991; 32: 
1754-1761. 
4. Johnson, E.W., De Lanerolle, N.C., Kim, J.H. et al. 
Central and peripheral benzodiazepine r ceptors: 
opposite changes in human epileptogenic t ssue. Neur- 
ology 1992; 42: 811-815. 
5. Savic, I., Persson, A., Roland, P., Pauli, S., Sedwall, G. 
and Widen, L. Iri-vivo demonstration f reduced benzo- 
diazepine receptor binding in human epileptic foci. 
Lancet 1988; 2: 863-866. 
6. Wedel, R., Stodieck, S.R.G., Steinhoff, B.J., Leinsinger, 
G. and Paulus, W. 99m-Tc-HMPAO- und 123-J- 
Iomazenil-SPECT zur Fokuslokalisation bei Epilep- 
sien. In: Stephan, H., ed. Epilepsie 92. Berlin: 
Deutsche Sektion der Internationalen Liga gegen Epi- 
lepsie, Berlin, 1993: pp. 175-180. 
7. Innis, R.B., Malison, R.T., Al-Tikriti, M. et al. Amphe- 
tamine-stimulated dopamine release competes in vivo 
for I '2:'IIIBZM binding to the D2 receptor in nonhuman 
primates. Synapse 1992; 10: 177-184. 
8. De Lanerolle, N.C., Brines, M., Williamson, A., Kim, 
J.H. and Spencer, D.D. Neurotransmitters and their 
receptors in human temporal lobe epilepsy. Epilepsy 
Research 1992; 7: 235-251. 
9. Sloviter, R.S. Feedforward and feedback inhibition of 
hippocampal principal cell activity evoked by perfor- 
ant path stimulation. Hippocampus 1991; 1: 31-40. 
10. Post, R.M. Time course of clinical effects of carbamaze- 
pine: Implications for mechanisms of action. Journal of 
Clinical Psychiatry 1988; 49: 35-46. 
11. Rechtschaffen, A. and Kales, A. A manual of standard- 
ized terminology, techniques and scoring system for 
sleep stages of human subjects. Washington: NIH, 
1968: pub. No. 204. 
